

---

**Product Data Sheet**

---

Product Name: RGH-5526 (GYKI-11679)

Cat. No.: GC32606

**Chemical Properties**

Cas. No. 69579-13-1

SMILES C/C(CC(OC(C)(C)C)=O)=N\NC1=NN=C(N2CCOCC2)C=C1Formula  $C_{16}H_{25}N_5O_3$  M.Wt 335.4

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Rats are used and treated with GYKI-11679 (0.5 mL of 1% Tween 80 suspension) at various dosages. They are killed at the specified times by decapitation; the heart is immediately removed, cut open, and rinsed in an isotonic saline solution. The brain is placed on ice and the hypothalamus is dissected. The tissues are weighed, homogenized in 5% trichloroacetic acid (TCA) containing 0.2% EDTA and ascorbic acid, and centrifuged for 1 h at 5000×g. The supernatant is processed on alumina and noradrenaline in the eluate is determined spectrofluorimetrically[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

## Product Data Sheet

---

### References:

[1]. Huszti Z, et al.  
Influence on  
turnover and level  
of hypothalamic  
noradrenaline by a  
new  
antihypertensive  
agent (GYKI 11679).  
J Neurochem. 1981  
Nov;37(5):1272-81.

### Background

GYKI-11679 is a new antihypertensive agent.

GYKI-11679 is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of GYKI-11679, and this effect lasts for 4 to 6 h. It is demonstrated that GYKI-11679 exerts a greater NA lowering effect in the hypothalamus than in the periphery. GYKI-11679 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1].

[1]. Huszti Z, et al. Influence on turnover and level of hypothalamic noradrenaline by a new antihypertensive agent (GYKI 11679). J Neurochem. 1981 Nov;37(5):1272-81.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA